Bladder preservation with Panitumumab and radiotherapy.
Recruiting
- Conditions
- Bladder carinoma, preservation, radiotherapy, Panitumumab
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 31
Inclusion Criteria
1. Signed written informed consent;
2. Histologically confirmed bladder carcinoma stage (including previous treatment):
Exclusion Criteria
1. Evidence of M+ (all patients will undergo a pelvic lymphadenectomy prior to chemoradiation);
2. Prior chemotherapy or radiotherapy to the pelvis;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acute Toxicity rate during radiotherapy with Panitumumab treatment.
- Secondary Outcome Measures
Name Time Method 1. Complete response rate at 3 months;<br /><br>2. Local control rate at 6, 12, and 18 months, and at 2 years;<br /><br>3. Bladder preservation rate;<br /><br>4. Any grade 3 or 4 adverse event during and within one month after completion of therapy.